Feasibility of Tomotherapy to spare the cochlea from excessive radiation in head and neck cancer

Oral Oncology

Volumn 47, Issue 5, 2011, Pages 414-419

  Nguyen, Nam P ^a   Smith Raymond, Lexie ^a   Vinh Hung, Vincent ^b   Sloan, Devin ^a   Davis, Rick ^a   Vos, Paul ^c   Abraham, Dave ^a   Stevie, Michelle ^a   Krafft, Shane Paul ^a   Ly, Bevan Hong ^d   Ries, Tiffany ^a   Karlsson, Ulf ^e   Ceizyk, Misty ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c EAST CAROLINA UNIVERSITY   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e MARSHFIELD CLINIC   (United States)

Author keywords

Cochlea sparing; Head and neck cancer; Tomotherapy

Indexed keywords

COCHLEA; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TOMOTHERAPY;

EID: 79956208323     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2011.03.011     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58(2):71-96.
2. Shiboski CH, Schmidt BL, Jordan RCK. Tongue and tonsil carcinoma. Increasing trends in the US population age 22-44 years. Cancer 2005;103(9):1843-9.
3. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomized comparison. Br J Cancer 2005;93(3):270-86.
4. Chung YL, Lee MY, Horng CF, et al. Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiation alone. Head Neck 2009;31(1):9-20.
5. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16, and EGFR expression expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007;120(8):1731-8. (Pubitemid 46399359)
6. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone with Docitaxel in head and neck cancer. N Engl J Med 2007;357(17):1705-15. (Pubitemid 350005152)
7. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent radiotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804. (Pubitemid 28277960)
8. Hellberg V, Wallin I, Eriksson S, et al. Cisplatin and Oxaloplatin toxicity: importance of cochlea kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009;101(1):37-47.
9. Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 2006;24(6):918-24. (Pubitemid 46638845)
10. Nagy JL, Adelstein DJ, Newman CW, et al. Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol 1999;22(3):305-8. (Pubitemid 30263329)
11. Chen WC, Jackson A, Budnick AS, et al. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer 2006;106(4):820-9. (Pubitemid 43238449)
12. Hitchcock YJ, Tward JD, Szabo A, et al. Relative contribution of radiotherapy and cisplatin-based chemotherapy to sensori-neural hearing loss in head and neck cancer patients. Int J Radiat Oncol Biol Phys 2009;73(3):779-88.
13. Low WK, Toh ST, Wee J, et al. Sensori-hearing loss after chemotherapy and radiochemotherapy. J Clin Oncol 2006;24(12):1904-9.
14. Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharyngeal cancer: update of the Memorial Sloan Kettering experience. Int J Radiat Oncol Biol Phys 2006;64(1):57-62. (Pubitemid 41831209)
15. Cohen SM, Turley R. Coprevalence and impact of dysphonia and hearing loss in the elderly. Laryngoscope 2009;119(9):1870-3.
16. Monzani D, Galeazzi GM, Genovese E, et al. Psychology profile and behavior of working adults with mild or moderate hearing loss. Acta Otorhinolaryngol Ital 2009;28(2):61-6.
17. Dawson LA, Jaffray DA. Advanced in image-guided radiotherapy. J Clin Oncol 2007;25(8):938-46.
18. Beavis AW. Is Tomotherapy the future of IMRT? Br J Radiol 2004;77:285-95.
19. Nguyen NP, Ceizyk M, Vos P, et al. Effectiveness of image-guided radiotherapy for laryngeal sparing in head and neck cancer. Oral Oncol 2010;46:283-6.
20. Pacholke HD, Amdur RJ, Schmalfuss IM, et al. Contouring the middle and inner ear on radiotherapy planning scans. Am J Clin Oncol 2005;28:143-7.
21. Pan CC, Eisbruch A, Lee JS, et al. Prospective study of inner ear radiation dose and hearing loss in head and neck cancer patients. Int J Radiat Oncol Biol Phys 2005;61(5):1393-402. (Pubitemid 40470420)
22. Laskar S, Bahl G, Muckaden MA, et al. Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy. Int J Radiat Biol Phys 2008;72:728-36.
23. Chau RM, Leung SF, Kam MKM, et al. A split organ approach for dose optimization for intensity-modulated radiotherapy for advanced T-stage nasopharyngeal carcinoma. Clin Oncol 2008;20(2):134-41. (Pubitemid 351194286)
24. Kodaira T, Tomita N, Tachibana H, et al. Aichi cancer center initial experience of intensity modulated radiation therapy for nasopharyngeal cancer using helical Tomotherapy. Int J Radiat Biol Phys 2009;73(4):1129-34.
25. Poon I, Xia P, Weinberg V, et al. A treatment planning analysis of inverse planned and forward planned intensity modulated radiation therapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:1625-33. (Pubitemid 350116422)
26. Sultanem K, Shu HK, Xia P, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the university of California San Francisco experience. Int J Radiat Oncol Biol Phys 2009;48:711-22.
27. Taheri-Kadkhoda Z, Bjork-Eriksson T, Nill S, et al. Intensity-modulated radiotherapy for nasopharyngeal carcinoma: a comparative treatment planning study of photons, protons. Radiat Oncol 2008;3:4.
28. Rosenthal DI, Chambers MS, Fuller CD, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;72(3):747-52.
29. De Arruda FF, Puri DR, Zhung J, et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering cancer center experience. Int J Radiat Oncol Biol Phys 2006;64(2):363-73. (Pubitemid 43083420)
30. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma. Cancer 2008;113(3):497-507.
31. Lee NY, O'Meara WO, Chan K, et al. Concurrent chemotherapy and intensity-modulated radiotherapy for locally advanced laryngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2007;69(2):459-68. (Pubitemid 47380087)
32. Gomez DR, Zhung JE, Gomez J, et al. Intensity-modulated radiotherapy for postoperative treatment of oral cavity cancers. Int J Radiat Biol Phys 2009;73(4):1096-103.
33. Nutting CM, Rowbottom CG, Cosgrove VP, et al. Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother Oncol 2001;60(2):163-72. (Pubitemid 32601969)
34. Klem ML, Mechalakos JG, Wolden SL, et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Biol Phys Oncol 2008;70(4):1100-7. (Pubitemid 351296099)
35. Lee N, Xia P, Fischbein NJ, et al. Intensity-modulated radiotherapy for head and neck cancer: the UCSF experience focusing on target delineation. Int J Radiat Oncol Biol Phys Oncol 2003;57(1):49-60. (Pubitemid 36959738)
36. Zuur CL, Simis YJ, Lamers EA, et al. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 2009;74(2):490-6.
37. Mackie TR, Kapatoes J, Ruchala K, et al. Image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(1):89-105. (Pubitemid 36403680)
38. Wang W, Yang H, Hu W, et al. Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2010;77(2):617-21.
39. Honore HB, Bentzen SM, Moller K, et al. Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiother Oncol 2002;65:9-16. (Pubitemid 35284460)
40. Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys 2009;73(5):1335-42.
41. Ylmaz YF, Avtas FI, Akdogan O, et al. Sensorineural hearing loss after radiotherapy for head and neck tumors: a prospective study of the effect of radiation. Otol Neurotol 2008;29(4):461-3.
42. Wang LF, Kuo WR, Ho KY, et al. A long-term study on on hearing status in patients with nasopharyngeal carcinoma after radiotherapy. Otol Neurotol 2004;25(2):168-73.
43. Hogan A, O'Laughlin K, Davis A, et al. Hearing loss and paid employment: Australian population survey finding. Int J Audiol 2009;48(3):117-22.
44. McDonnall MC. Risk factors for depression among older adults with dual sensory loss. Aging Mental Health 2009;13(4):569-76.
45. Nguyen NP, Chi A, Nguyen LM, et al. Human papillomavirus associated oropharyngeal cancer: a new clinical entity. QJM 2010;103(4):229-36.
46. Klozar J, Kratochvil V, Salakova M, et al. HPV status and regional metastasis in the prognosis of oral and oropharyngeal cancer. Eur Arch Otolaryngol 2008;265:S75-82.